InvestmentJun 18, 2026, 04:02 AM
Alvotech Launches Public Offering, Eyes $125M in Proceeds
AI Summary
Alvotech has announced the commencement of an underwritten public offering of its ordinary shares, with an option for underwriters to purchase additional shares. The company anticipates raising approximately $125 million through this offering and a concurrent private placement. The net proceeds are earmarked for the continued development of its biosimilar assets, working capital, and general corporate purposes. BofA Securities, Jefferies, and Evercore ISI are serving as joint book-running managers for the offering.
Key Highlights
- Alvotech commences underwritten public offering of ordinary shares.
- Company expects to grant underwriters a 30-day option to purchase up to an additional 15% of shares.
- Alvotech anticipates gross proceeds from the offering and concurrent private placement to be approximately $125 million.
- Net proceeds will fund continued development of biosimilar assets, working capital, and general corporate purposes.
- BofA Securities, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.
Price Impact
More from ALVO